Empowering innovative science and transformativetherapeutics

Adcendo aps is a biotech company developing novel targeted anti-cancer therapies based on antibody-drug conjugates (adcs).

Anaconda BioMed, headquartered in Barcelona, Spain, is among the world’s most innovative early stage medical technology companies.

Aura Biosciences is applying nanotechnology to the fight against cancer. Its novel viral nanoparticle technology, developed in partnership with the National Cancer Institute (NCI), harnesses the potential of viral evolution and tumor targeting for the treatment of cancer.

BioVex was a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease using oncolytic viruses.

CorWave is a French medtech company developing next-generation blood pumps for heart failure patients.

CytoKi Pharma is a biotechnology company engaged in the development of protein drugs for diseases characterized by epithelial injury, with focus on developing a licensed long-acting IL-22 program for Inflammatory Bowel Disease and potentially additional clinical indications.

Endosense was a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias.

Engrail is a clinical-stage pharmaceutical company with the aspiration of becoming a leader in neuroscience.

Next-Generation Radiopharmaceuticals for precision medicine.

KALA BIO (previosuly Kala Pharmaceuticals) is developing treatments that focus the power of its MSC-S platform on significant unmet needs across a range of rare ophthalmic diseases.

Kynexis is a precision medicine-based biotech company developing a novel drug to treat cognitive impairment in patients with schizophrenia.

LAVA Therapeutics is developing a proprietary bispecific antibody platform that engages gamma-delta T cells for the treatment of hematological and solid cancers.

Memo is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with virus infections and cancer.

Mineralys Therapeutics is a private, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension.

Minoryx is a clinical-stage biotech company developing new therapies for orphan CNS diseases with a high unmet medical need. The company’s lead program leriglitazone (MIN-102) has completed a Phase II/III clinical trial for the treatment of adrenomyeloneuropathy, the most common phenotype of X-linked Adrenoleukodystrophy, and a Phase II study in Friedreich’s Ataxia.

Neurona is a clinical-stage biotherapeutics company developing regenerative cell therapies that permanently integrate into neural circuits, replace affected cells, and rebalance dysregulated electrical activity to repair the nervous system.

NorthSea Therapeutics is a Clinical-stage biotech company with the aim to develop novel and innovative therapeutic strategies for NASH and other metabolic, inflammatory and fibrotic diseases.

Ona Therapeutics is a biotech company, spin-off of ICREA and IRB, specialized in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism

ReproNovo is a cutting-edge biopharmaceutical company developing innovative solutions to address critical gaps in reproductive medicine and women’s health.

Sanifit is a clinical-stage biopharmaceutical company focused on the development of SNF472, an experimental drug for the treatment of cardiovascular diseases linked to calcification in the end-stage renal disease population undergoing haemodialysis.

SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases.

Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases.

STAT-DX was developin near-patient testing products for healthcare professionals with short turnaround time applications and critical care.

Synendos Therapeutics is a biopharmaceutical company developing a new class of small molecules aimed at restoring the natural functioning of the endocannabinoid system in the brain with the potential for treating a wide range of Central Nervous System (CNS)

Tagworks is a platform company developing click cleavable therapeutics for oncology and other indications.

Initial investment in Cellerix, founded in 2004. Cellerix was a biopharmaceutical company developing innovative treatments based on a cell therapy. Subsequently it reverse-merged with Tigenix listed on Euronext. Tigenx was Acquired in July 2018 by Takeda Pharmaceuticals.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, founded in 2016, that is specialized in the discovery and development of therapeutic proteins for the prevention and treatment of bleeding. The company’s leading product in development, VMX-C001, is a new therapeutic protein to prevent or stop severe bleeding in patients taking blood thinners in the form of direct factor Xa inhibitors.

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases including Wilson Disease, Progressive Familiar Intrahepatic Cholestasis (PFIC) and other indications. Vivet is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long-term expression.